IHT Wealth Management LLC decreased its holdings in Celgene Co. (NASDAQ:CELG) by 41.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,179 shares of the biopharmaceutical company’s stock after selling 2,243 shares during the period. IHT Wealth Management LLC’s holdings in Celgene were worth $316,000 as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. First PREMIER Bank purchased a new stake in shares of Celgene during the 3rd quarter valued at about $26,000. Liberty Wealth Management LLC boosted its holdings in Celgene by 212.8% in the second quarter. Liberty Wealth Management LLC now owns 294 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 200 shares during the last quarter. B & T Capital Management DBA Alpha Capital Management purchased a new stake in Celgene in the third quarter worth approximately $28,000. Massey Quick Simon & CO. LLC bought a new stake in Celgene in the 2nd quarter worth approximately $33,000. Finally, Lenox Wealth Advisors LLC bought a new stake in Celgene in the 3rd quarter worth approximately $37,000. Hedge funds and other institutional investors own 71.66% of the company’s stock.
In other Celgene news, insider Terrie Curran sold 11,338 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $98.27, for a total transaction of $1,114,185.26. Following the sale, the insider now owns 13,493 shares in the company, valued at approximately $1,325,957.11. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.39% of the stock is currently owned by company insiders.
Shares of CELG opened at $108.24 on Tuesday. The business has a 50-day simple moving average of $106.93 and a two-hundred day simple moving average of $98.37. The company has a quick ratio of 2.80, a current ratio of 2.89 and a debt-to-equity ratio of 1.51. Celgene Co. has a 52 week low of $58.59 and a 52 week high of $110.70. The stock has a market cap of $77.04 billion, a price-to-earnings ratio of 14.22, a PEG ratio of 0.51 and a beta of 1.41.
Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $2.99 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.70 by $0.29. The firm had revenue of $4.52 billion for the quarter, compared to analysts’ expectations of $4.39 billion. Celgene had a return on equity of 78.15% and a net margin of 34.63%. The business’s quarterly revenue was up 16.1% on a year-over-year basis. During the same period in the previous year, the firm earned $2.29 EPS. On average, equities analysts anticipate that Celgene Co. will post 10.7 earnings per share for the current fiscal year.
Several equities analysts have recently weighed in on the company. BidaskClub cut Celgene from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 19th. Standpoint Research lowered Celgene from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Leerink Swann set a $115.00 price objective on Celgene and gave the company a “hold” rating in a research report on Friday, November 1st. Wells Fargo & Co set a $110.00 target price on Celgene and gave the stock a “hold” rating in a research report on Friday, November 1st. Finally, Mizuho restated a “hold” rating and set a $100.00 price target on shares of Celgene in a research note on Sunday, October 20th. One research analyst has rated the stock with a sell rating, nineteen have given a hold rating and two have assigned a buy rating to the company’s stock. Celgene presently has a consensus rating of “Hold” and a consensus target price of $97.31.
Celgene Company Profile
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Read More: What does a neutral rating on stocks mean?
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.